Syntex (u.s.a.) Inc.

Roche Palo Alto LLC

Other

Palo Alto LLC

F. Hoffmann-la Roche Ag

David Garrett Loughhead

Robert James Weikert

David Bernard Smith

David John Morgans, Jr

Eric Brian Sjogren

Ronald Charles Hawley

Peter H Nelson

John W Patterson

Todd Richard Elworthy

Teresa Lara

Dean R Artis

Alicia Cervantes

Ann M Waltos

Fidencio Franco

Alejandra Trejo

Counde O'Yang

Mario Fernandez

Francisco X Talamas

Lee Allen Flippin

Mario Fern Andez

Francisco X Talam As

Michael Soth

John C Rohloff

David George Putman

Xiao-Fa Lin

Sanja Novakovic

Hans Maag

Jacob Berger

David Nigel Hurst

Daisy Joe Du Bois

Richard Leo Cournoyer

Jason Manka

Xao-Fa Lin

Fancisco X Talamas

John Cureton Hunter

Compounds of the formula: wherein Ar, Ar, Rand Rare as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.

Cyclopropyl aryl amide derivatives and uses thereof

This invention relates to a method for modulating &#x3b1;subtype GABAreceptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to novel heteocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain 

[object Object]

This invention relates to a method for modulating &#x3b1;subtype GABAreceptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to said heterocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain 

Heterocyclic GABAA subtype selective receptor modulators

This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ar is optionally substituted aryl or heteroaryl, R-Rare as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

Ring fused pyrazole derivatives as CRF antagonists

This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ris optionally substituted aryl or heteroaryl, Rand Rare as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

Indazole derivatives as CRF antagonists

This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ar is optionally substituted aryl or heteroaryl, R&#x2013;Rare as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

Compounds selected from the group of compounds represented by Formula I:

Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain

Compounds selected from the group of compounds represented by Formula I: ##STR1## as an individual isomer or as a racemic or non-racemic mixture of isomers, and their pharmaceutically acceptable salts and N-oxides thereof; are sodium channel blockers, and thus exhibit useful pharmacological properties, including utility for the treatment of neuropathic pain conditions.

Phenoxymethyl piperidine derivatives for the treatment of neuropathic

This invention relates to a compound of the Formula I: ##STR1## as a racemic mixture and its individual enantiomers, in particular the (R)-enantiomer, and their pharmaceutically acceptable salts. These compounds are useful as sodium channel blockers, and are particularly useful for the alleviation of neuropathic pain.

Treatment of neuropathic pain

The disclosed hexenoic acid side-chain derivatives of mycophenolic acid are therapeutic agents advantageous in the treatment of disease states indicated for mycophenolic acid and/or mycophenolate mofetil, including immune, inflammatory, tumor, proliferative, viral or psoriatic disorders.

5-substituted derivatives of mycophenolic acid

The disclosed derivatives of mycophenolic acid are therapeutic agents advantageous in the treatment of disease states indicated for mycophenolic acid and/or mycophenolate mofetil and other immunosuppressant agents.

4-amino 6-substitutes mycophenolic acid and derivatives

4-amino derivatives of 5-substituted mycophenolic acid

The disclosed 6-substituted derivatives of mycophenolic acid are therapeutic agents advantageous in the treatment of disease states indicated for mycophenolic acid and/or mycophenolate mofetil.

6-substituted mycophenolic acid and derivatives

Method of using 4-amino 6-substituted mycophenolic acid and derivatives

Growing community of inventors

Belmont, CA, United States of America

David Garrett Loughhead